🚀Check out this recent publication from the mTOR Pathway Diseases node - Challenges and opportunities from bench to bedside and the mTOR node tinyurl.com/mTORnode @BatemanLab @CharlotteRTye

We’re delighted to announce a new partnership between Oxford StemTech, @KingsCollegeLon, and MaxWell Biosystems, funded by @Innosuisse. Many patients with #epilepsy struggle with limited treatment options to manage their seizures effectively. To address this, our collaboration is focused on creating a high-throughput #drugtesting platform using physiologically relevant models. King’s will provide access to epilepsy patients. By integrating Oxford StemTech’s ReproPlex #iPSC reprogramming technology with MaxWell Biosystems’ advanced MaxTwo HD-#MEA (High-Density Microelectrode Array) System featuring a 24-well plate format, we can simultaneously analyze multiple patient-specific brain assembloids. This approach will provide a unique platform to understand epilepsy better and test potential new treatments with precision. We are excited to work together on this project and look forward to contributing to advancements in epilepsy research. Please refer to our website for more details 👉mxwbio.com/company/projects-… Stay tuned for updates!

A huge thank you to @BatemanLab from King's College London, who gave a fantastic seminar on the 'Mechanistic insight into the role of mTOR signalling in rare neurological diseases' today as part of our lunchtime seminar series.

Interested in researching neurodevelopmental disorders using iPSCs? Take a look at our iCASE PhD studentship, together with @NCNDgroup_KCL, to study mTORopathies kcl-mrcdtp.com/project/devel… @KCL_MRCDTP @KingsIoPPN findaphd.com/phds/project/de…